In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 10, 2012, Pages 1445-1451

  Zhao, Kai ^a   Ding, Ming ^a   Cao, Hui ^a   Cao, Zheng Xin ^b  

^a Jiangsu Province Jintan People's Hospital Clinical Laboratory   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

glycyrrhetinic acid; human liver microsomes; inhibition; interaction; metabolism

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; GLYCYRRHETINIC ACID; ISOENZYME; MEPHENYTOIN; MIDAZOLAM; PHENACETIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; RAT; TANDEM MASS SPECTROMETRY;

ALCOHOL OXIDOREDUCTASES; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84865860995     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01516.x     Document Type: Article

References (22)

1. Hattori M, et al,. Metabolism of glycyrrhizin by human intestinal flora. Planta Med 1983; 48: 38-42. (Pubitemid 13068054)
2. Pompei R, et al,. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature (London) 1979; 281: 689-690. (Pubitemid 10249050)
3. Sasaki H, et al,. Effect of glycyrrhizin, an active component of licorice roots, on HIV replication in cultures of peripheral blood mononuclear cells from HIV-seropositive patients. Pathobiology 2002/2003; 70: 229-236. (Pubitemid 36829003)
4. Finney RSH, Somers GF,. The antiinflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol 1958; 10: 613-620.
5. Fujisawa K, et al,. Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med J 1980; 23: 745-756. (Pubitemid 11187451)
6. Hirabayashi K, et al,. Antiviral activities of glycyrrhizin and its modified compounds against human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1) in vitro. Chem Pharm Bull 1991; 39: 112-115.
7. Gao K, et al,. CYP3A1/2 and 2C9/10 in rat liver microsomes mediate 22 < alpha >-and 24-hydroxylation of 18 < alpha >-GA. Chin J Clin Pharmacol Ther 2007; 11: 1255-1306.
8. Ingelman-Sundberg M,. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology 2002; 181-182: 447-452. (Pubitemid 36015735)
9. Bjornsson TD, et al,. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-832. (Pubitemid 36759050)
10. Nobumitsu H, et al,. In vitro metabolism of chlorotriazines: characterization of simazine, atrazine, and propazine metabolism using liver microsomes from rats treated with various cytochrome P450 inducers. Toxicol Appl Pharmacol 1999; 156: 195-205.
11. Tang J, et al,. In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem Biol Interact 2002; 141: 229-241. (Pubitemid 35217762)
12. Weaver R, et al,. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 2003; 31: 955-966. (Pubitemid 36759067)
13. Kim KB, et al,. In vitro metabolism of a novel PPAR agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s. Xenobiotica 2008; 38: 1165-1176.
14. Yao HT, et al,. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci 2006; 79: 2432-2440.
15. Walsky RL, Obach RS,. Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 647-660. (Pubitemid 38668158)
16. Zhou Q, et al,. Prediction of metabolic drug interaction in vivo by using in vitro drug metabolism Data. Chin J Clin Pharmacol 2003; 19: 128-133.
17. Kim KA, et al,. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes. Drug Metab Dispos 2003; 31: 1227-1234.
18. Kim H, et al,. Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028. Toxicol Lett 2006; 166: 105-114. (Pubitemid 44291961)
19. Tang J, et al,. In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam. Chem Biol Interact 2004; 147: 319-329. (Pubitemid 38591501)
20. Shou M, et al,. Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 1999; 340: 845-853. (Pubitemid 29312885)
21. Guengerich FP,. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997; 43: 7-35.
22. Halpert JR,. Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 1995; 35: 29-53.